Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

Grunenthal Acquires Bayer Cancer Drug Stivarga

Analysis based on 9 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026

Sentiment
5
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal is a modest, bolt-on asset sale for Bayer that trims a non-core oncology product while providing a small cash inflow, with limited effect on Bayer's overall valuation. For privately held Grunenthal, it is an accretive, low-risk expansion of its commercial portfolio, with the main market relevance being the modest transfer of an established oncology asset and its future revenue stream.

pharmaceuticals healthcare biotechnology

Grunenthal, a privately held German pharmaceutical company focused on pain management, announced an agreement with Bayer to acquire the cancer treatment Stivarga (regorafenib) for up to 375 million euros. Stivarga is an oral multikinase inhibitor approved in more than 90 markets for metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma. The transaction is subject to customary closing conditions, including approval by relevant regulatory authorities, and is expected to close by the end of 2026 or early 2027. Grunenthal estimates the medicine could contribute up to approximately 100 million euros to its consolidated EBITDA for the year ending 31 December 2027, assuming closing and full-year consolidation. Loss of exclusivity for Stivarga is anticipated in 2029 in the European Union and 2030 in the United States. The deal is the latest step in Grunenthal's M&A strategy of acquiring established medicines, following prior transactions including global rights to Nebido, rights to Cialis in Mexico, Brazil and Colombia, European Union — European rights to Crestor and Nexium, and other products. Grunenthal has invested around 2.6 billion euros in M&A transactions since 2017. CEO Gabriel Baertschi said the acquisition is immediately accretive and a strong strategic fit. Freshfields served as legal counsel to Grunenthal.

95 Grünenthal acquired Bayer
20 Grünenthal acquired full ownership Kyowa Kirin
priv
Grunenthal is the acquirer of Stivarga, paying up to 375 million euros to expand its established medicines portfolio. The deal is expected to be immediately accretive and add up to about 100 million euros to EBITDA by 2027.
Importance 100.0 Sentiment 20.0
stock
Bayer is the seller of Stivarga, divesting a non-core oncology asset for up to 375 million euros. The transaction modestly streamlines its portfolio and provides a small cash inflow.
Importance 90.0 Sentiment 5.0
per
Grunenthal CEO Gabriel Baertschi publicly framed the acquisition as a strong strategic fit and immediately accretive to the business.
Importance 30.0 Sentiment 10.0
cnt
The United States is a key market for Stivarga, where loss of exclusivity is anticipated in 2030 and where regulatory approval for the deal is required.
Importance 15.0 Sentiment 0.0
cnt
Germany is the headquarters country of Grunenthal, the acquirer in this transaction.
Importance 15.0 Sentiment 0.0
alliance
The European Union is a key market for Stivarga, where loss of exclusivity is anticipated in 2029 and where regulatory approval for the deal is required.
Importance 15.0 Sentiment 0.0
stock
Kyowa Kirin is referenced as the former joint venture partner of Grunenthal Meds, whose full ownership Grunenthal acquired earlier in 2026, illustrating Grunenthal's ongoing M&A strategy.
Importance 10.0 Sentiment 0.0
priv
Freshfields served as legal counsel to Grunenthal on the Stivarga acquisition.
Importance 10.0 Sentiment 0.0
curr
The euro is the currency in which the up to 375 million euro transaction value and the projected EBITDA contribution are denominated.
Importance 10.0 Sentiment 0.0
cnt
Japan is referenced in the context of prior Grunenthal product rights exclusions for Vimovo and Zomig, part of its M&A history.
Importance 5.0 Sentiment 0.0
cnt
Mexico is mentioned as a market where Grunenthal previously acquired rights to Cialis, part of its broader M&A track record.
Importance 5.0 Sentiment 0.0
cnt
Brazil is mentioned as a market where Grunenthal previously acquired rights to Cialis, part of its broader M&A track record.
Importance 5.0 Sentiment 0.0
cnt
Colombia is mentioned as a market where Grunenthal previously acquired rights to Cialis, part of its broader M&A track record.
Importance 5.0 Sentiment 0.0
Bayer related ↔ United States
United States strained ally ↔ Germany The United States considers Germany a crucial NATO ally and important trade partner, but has initiated tariffs and troop
United States ally ↔ Japan The United States considers Japan a cornerstone defense ally and a vital economic partner in the Indo-Pacific, with exte
Germany related ↔ European Union
Germany related ↔ Japan
European Union related ↔ Japan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.